<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">12677</article-id><article-id pub-id-type="doi">10.7554/eLife.12677</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Short Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Chromosomes and Gene Expression</subject></subj-group></article-categories><title-group><article-title>Nucleosomes impede Cas9 access to DNA <italic>in vivo</italic> and <italic>in vitro</italic></article-title></title-group><contrib-group><contrib contrib-type="author" id="author-45857"><name><surname>Horlbeck</surname><given-names>Max A</given-names></name><aff><institution content-type="dept">Department of Cellular and Molecular Pharmacology, California Institute for Quantitative Biomedical Research</institution>, <institution>Howard Hughes Medical Institute, University of California, San Francisco</institution>, <addr-line><named-content content-type="city">San Francisco</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-45858"><name><surname>Witkowsky</surname><given-names>Lea B</given-names></name><aff><institution content-type="dept">Department of Molecular and Cell Biology, Li Ka Shing Center for Biomedical and Health Sciences</institution>, <institution>Howard Hughes Medical Institute, University of California, Berkeley</institution>, <addr-line><named-content content-type="city">Berkeley</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-45859"><name><surname>Guglielmi</surname><given-names>Benjamin</given-names></name><aff><institution content-type="dept">Department of Molecular and Cell Biology, Li Ka Shing Center for Biomedical and Health Sciences</institution>, <institution>Howard Hughes Medical Institute, University of California, Berkeley</institution>, <addr-line><named-content content-type="city">Berkeley</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-45860"><name><surname>Replogle</surname><given-names>Joseph M</given-names></name><aff><institution content-type="dept">Department of Cellular and Molecular Pharmacology, California Institute for Quantitative Biomedical Research</institution>, <institution>Howard Hughes Medical Institute, University of California, San Francisco</institution>, <addr-line><named-content content-type="city">San Francisco</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-45861"><name><surname>Gilbert</surname><given-names>Luke A</given-names></name><aff><institution content-type="dept">Department of Cellular and Molecular Pharmacology, California Institute for Quantitative Biomedical Research</institution>, <institution>Howard Hughes Medical Institute, University of California, San Francisco</institution>, <addr-line><named-content content-type="city">San Francisco</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-45864"><name><surname>Villalta</surname><given-names>Jacqueline E</given-names></name><aff><institution content-type="dept">Department of Cellular and Molecular Pharmacology, California Institute for Quantitative Biomedical Research</institution>, <institution>Howard Hughes Medical Institute, University of California, San Francisco</institution>, <addr-line><named-content content-type="city">San Francisco</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-5107"><name><surname>Torigoe</surname><given-names>Sharon E</given-names></name><aff><institution content-type="dept">Department of Molecular and Cell Biology, Li Ka Shing Center for Biomedical and Health Sciences</institution>, <institution>Howard Hughes Medical Institute, University of California, Berkeley</institution>, <addr-line><named-content content-type="city">Berkeley</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-23201"><name><surname>Tjian</surname><given-names>Robert</given-names></name><aff><institution content-type="dept">Department of Molecular and Cell Biology, Li Ka Shing Center for Biomedical and Health Sciences</institution>, <institution>Howard Hughes Medical Institute, University of California, Berkeley</institution>, <addr-line><named-content content-type="city">Berkeley</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" corresp="yes" id="author-30197"><name><surname>Weissman</surname><given-names>Jonathan S</given-names></name><aff><institution content-type="dept">Department of Cellular and Molecular Pharmacology, California Institute for Quantitative Biomedical Research</institution>, <institution>Howard Hughes Medical Institute, University of California, San Francisco</institution>, <addr-line><named-content content-type="city">San Francisco</named-content></addr-line>, <country>United States</country><email>Jonathan.Weissman@ucsf.edu</email></aff><xref ref-type="fn" rid="conf5"/></contrib></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-5892"><name><surname>Adelman</surname><given-names>Karen</given-names></name><role>Reviewing editor</role><aff><institution>National Institute of Environmental Health Sciences</institution>, <country>United States</country></aff></contrib></contrib-group><pub-date date-type="pub" publication-format="electronic"><day>17</day><month>03</month><year>2016</year></pub-date><elocation-id>e12677</elocation-id><history><date date-type="received"><day>29</day><month>10</month><year>2015</year></date><date date-type="accepted"><day>16</day><month>03</month><year>2016</year></date></history><permissions><copyright-statement>Â© 2016, Horlbeck et al</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Horlbeck et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><abstract><p>The prokaryotic CRISPR (Clustered Regularly Interspaced Palindromic Repeats)-associated protein, Cas9, has been widely adopted as a tool for editing, imaging, and regulating eukaryotic genomes. However, our understanding of how to select single-guide RNAs (sgRNAs) that mediate efficient Cas9 activity is incomplete, as we lack insight into how chromatin impacts Cas9 targeting. To address this gap, we analyzed large-scale genetic screens performed in human cell lines using either nuclease-active or nuclease-dead Cas9 (dCas9). We observed that highly active sgRNAs for Cas9 and dCas9 were found almost exclusively in regions of low nucleosome occupancy. <italic>In vitro</italic> experiments demonstrated that nucleosomes in fact directly impede Cas9 binding and cleavage, while chromatin remodeling can restore Cas9 access. Our results reveal a critical role of eukaryotic chromatin in dictating the targeting specificity of this transplanted bacterial enzyme, and provide rules for selecting Cas9 target sites distinct from and complementary to those based on sequence properties.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group></article-meta></front><back><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Max A Horlbeck, Filed a patent application related to CRISPRi screening techonology.</p></fn><fn fn-type="conflict" id="conf3"><p>Luke A Gilbert, Filed a patent application related to CRISPRi screening techonology.</p></fn><fn fn-type="conflict" id="conf4"><p>Robert Tjian, President of the Howard Hughes Medical Institute (2009-present), one of the three founding funders of eLife, and a member of eLife's Board of Directors.</p></fn><fn fn-type="conflict" id="conf5"><p>Jonathan S Weissman, Filed a patent application related to CRISPRi screeningtechonology.</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group></back></article>